USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…
USA The US heads for three leading international mid-cap innovators – Japanese firms Eisai and Kyowa Kirin and Danish outfit Lundbeck – explain their vital role leading operations in the world’s most innovative and lucrative pharma market, translating global cultures to a US reality, and the challenges of attracting and retaining…
USA PharmaBoardroom recently spoke to CNS-focused Danish biopharma company Lundbeck’s EVP and Head of North America Peter Anastasiou, who highlighted the long-term damage COVID-19 is causing to the general mental health of society, and how Lundbeck is well-positioned to address this in North America. As the global pandemic rages on,…
USA Industry veteran Peter Anastasiou, executive VP and head of North America for Danish CNS specialist Lundbeck, outlines the performance of Lundbeck’s specialty portfolio in the US market, the challenges of working in the CNS space, and how the company is adapting to the problems posed by the COVID-19 pandemic. …
Coronavirus With the global coronavirus pandemic still ongoing and teleworking having become the new normal, pharma executives from across the world are giving us their insights into how they are managing in the age of confinement to ensure continued employee welfare and the safe supply of medications to the patients and…
Mexico Sara Montero, managing director of Lundbeck Mexico, Central America and Andean countries since January 2020, explains her key priorities and the importance of the region for Lundbeck, highlights the current situation for mental illness in Latin America (LatAm) and outlines her objective to bring innovative treatments to Mexican patients. …
Sweden Richard Wikner, country manager of Lundbeck Sweden, explains the affiliate’s strategic significance to the research-based company and its role in raising awareness about mental illnesses in the region, in addition to the company’s mission of striving to help patients return to their normal lives following depression. [Sweden] still remains…
China China’s pharma market is growing at an unprecedented pace and has become a key element of virtually all pharma multinationals’ international strategies. However, with a spate of regulatory reforms being rolled out, it can be challenging for large organizations with headquarters located in slower-paced mature markets to adapt to China’s…
China Lorena Di Carlo, a Lundbeck veteran, shares her first impressions of her six months as general manager of Lundbeck China, the strategic significance of China to Lundbeck’s global organization, the company’s commitment to patient-centricity, disease awareness and medical education in the area of brain diseases, and her strategic priorities for…
Korea Pil Soo Oh has been the managing director of Lundbeck Korea since the establishment of the affiliate in 2002. Mr Oh offers his insights into Lundbeck’s footprint in Korea, their plans to adapt locally to Lundbeck’s new global strategy, and the issues of stigma towards mental illness in Korean society.…
France Lundbeck France and Benelux’s Lourdes Pla discusses Europe-wide restructuring, the importance of the French affiliate to the global group and the government’s attitude towards healthcare and neuroscience. We are the only specialty pharma player exclusively dedicated to neuroscience and it is important that this shines through in our dealings…
Malaysia Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to healthcare professionals and patients in the country. He also highlights his future plans for the affiliate to bring more innovative…
See our Cookie Privacy Policy Here